 Mesenchymal stem cells, MSCs, have been investigated as potential vehicles for delivering drugs to treat various diseases, including cancer. Despite their potential, MSCs have been found to be less efficient at reaching tumours than desired due to their poor homing ability and broad distribution throughout the body. To address this issue, researchers have developed several methods to increase the selectivity of MSCs to tumours, such as genetically modifying them or coating them with antibodies. In addition, novel imaging techniques have been developed to track MSCs in vivo and assess their biodistribution after infusion. These advances have allowed for more accurate comparison of different MSC-based drug delivery systems and have led to improved understanding of how MSCs interact with tumours. This article was authored by Timothy E. G. Kruger, Daniel L. J. Thorik, Samuel at Denmede and others.